RxDoctor Payments Data

Stephen Wilkerson, DO

Family Medicine · Tupelo, MSNPI 1790166841

Payments from drug & device makers

$1,357in general payments, 2019–2025

Across 78 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$303
  • AstraZeneca$260
  • Lilly USA, LLC$152
  • Xeris Pharmaceuticals, Inc.$144
  • Amgen$91
  • Corcept Therapeutics$73
  • plus $333 from 8 others

What the payments were for

  • Food & beverage$1,357100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,357 in reported general payments places this provider in the 60th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$3,067
Medicare patients
37
Services billed
38

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide167$262,449
EliquisApixaban217$152,292
JardianceEmpagliflozin153$137,742
FarxigaDapagliflozin Propanediol75$51,316
MounjaroTirzepatide30$45,637
Soliqua 100-33Insulin Glargine/Lixisenatide47$44,825
RybelsusSemaglutide19$43,197
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$40,273
JanuviaSitagliptin Phosphate46$38,367
LinzessLinaclotide34$26,136
XareltoRivaroxaban26$21,614
TrulicityDulaglutide14$21,111
EntrestoSacubitril/Valsartan36$20,763
Tresiba Flextouch U-100Insulin Degludec27$20,547
Tresiba Flextouch U-200Insulin Degludec22$19,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$303$305,647186 claims
Boehringer IngelheimJardiance$47$137,742153 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$260$67,744105 claims
Lilly USA, LLCMounjaro, Trulicity$152$66,74844 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$26$44,82547 claims
GSKTrelegy Ellipta$31$40,27353 claims
AbbVieLinzess$45$26,13634 claims
NovartisEntresto$21$20,76336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →